Skip to content

US · AKTS · BIOTECHNOLOGY

Aktis Oncology, Inc. (AKTS) intrinsic value and stock valuation

$16.15as of 2026-11-21 · Mkt cap 1.21B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aktis Oncology, Inc. DCF and intrinsic value

InvestorsCraft values AKTS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AKTS’s statements →

Aktis Oncology, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02210 aktisoncology.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$6.5M
20222025
Net income
-$-63.73M
20222025
Free cash flow
-$-73.71M
20222025
Total equity
-$-146.15M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$6.5M$1.49M$0.00$0.00
Operating income-$-74.68M-$-52.05M-$-34.79M-$-19.76M
Net income-$-63.73M-$-43.98M-$-28.64M-$-17.93M
EPSd-$-1.21M-$-1.26M-$-821.57K-$-514.34K
Operating cash flow-$-64.13M$14.8M-$-30M-$-18.12M
Capital expenditure-$-9.58M-$-2.86M-$-3.76M-$-2.31M
Free cash flow-$-73.71M$11.9M-$-33.77M-$-20.43M
Total assets$264.9M$326.2M$122.4M$138.3M
Total debt$11.6M$12M$13.4M$1.77M
Net debt-$-26.24M-$-25.15M-$-16.11M-$-126.82M
Total equity-$-146.15M-$-87.8M-$-46.31M-$-19.23M
Cash and short-term investments$226.8M$297.2M$97.9M$128.6M
Income statement
2025202420232022
Revenue$6.5M$1.49M$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00
Gross profit$6.5M$1.49M$0.00$0.00
Research and development expenses$67.5M$41M$25.9M$14.3M
Selling, general and administrative expenses$12.6M$11.3M$7.68M$5.11M
Other expenses$1.13M$1.28M$1.2M$360K
Operating expenses$81.2M$53.5M$34.8M$19.8M
Cost and expenses$81.2M$53.5M$34.8M$19.8M
Interest income$11M$8.1M$5.38M$1.65M
Interest expense$0.00$0.00$0.00$0.00
Depreciation and amortization$2.33M$1.57M$1.2M$450K
Ebitda-$-61.4M-$-42.41M-$-27.45M-$-17.48M
Operating income-$-74.68M-$-52.05M-$-34.79M-$-19.76M
Total other income/expenses, net$11M$8.07M$6.15M$1.83M
Income before tax-$-63.73M-$-43.98M-$-28.64M-$-17.93M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-63.73M-$-43.98M-$-28.64M-$-17.93M
Weighted average shares outstanding$52.5M$34.9M$34.9M$34.9M
Weighted average diluted shares outstanding$52.5M$34.9M$34.9M$34.9M
Balance sheet
2025202420232022
Cash and short-term investments$226.8M$297.2M$97.9M$128.6M
Net receivables$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$230.3M$300.9M$100.2M$132.5M
Property, plant and equipment, net$27.3M$20.9M$20.9M$4.87M
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$34.6M$25.3M$22.2M$5.84M
Total assets$264.9M$326.2M$122.4M$138.3M
Accounts payable$1.74M$1.92M$960K$490K
Short-term debt$1.31M$1.3M$1.53M$850K
Deferred revenue$18.7M$9.28M$0.00$0.00
Total current liabilities$31.2M$18.8M$6.24M$5.28M
Long-term debt$10.2M$10.7M$11.9M$920K
Deferred revenue, non-current$36.2M$51M$0.00$0.00
Total non-current liabilities$379.8M$395.2M$162.4M$152.3M
Capital lease obligations$11.6M$12M$13.4M$1.77M
Total liabilities$411M$414M$168.7M$157.6M
Common stock$0.00$0.00$0.00$0.00
Retained earnings-$-156.56M-$-92.83M-$-48.85M-$-20.21M
Accumulated other comprehensive income (loss)$40K$120K$80K$0.00
Total equity-$-146.15M-$-87.8M-$-46.31M-$-19.23M
Total investments$189M$260M$68.4M$0.00
Total debt$11.6M$12M$13.4M$1.77M
Net debt-$-26.24M-$-25.15M-$-16.11M-$-126.82M
Cash flow statement
2025202420232022
Net income-$-63.73M-$-43.98M-$-28.64M-$-17.93M
Depreciation and amortization$2.33M$1.57M$1.12M$450K
Stock-based compensation$5.13M$2.26M$1.48M$700K
Change in working capital-$-3.23M$59M-$-10K-$-1.14M
Accounts receivable$1.03M-$-860K-$-260K$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable-$-40K$360K$660K-$0.00
Net cash provided by operating activities-$-64.13M$14.8M-$-30M-$-18.12M
Investments in property, plant and equipment-$-9.58M-$-2.86M-$-3.76M-$-2.31M
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities$66M-$-190.4M-$-68.83M-$-2.31M
Common stock issued$340K$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-1.21M$183.3M$0.00$120M
Net change in cash$620K$7.65M-$-98.83M$99.6M
Cash at end of period$38.9M$38.3M$30.7M$129.5M
Operating cash flow-$-64.13M$14.8M-$-30M-$-18.12M
Capital expenditure-$-9.58M-$-2.86M-$-3.76M-$-2.31M
Free cash flow-$-73.71M$11.9M-$-33.77M-$-20.43M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aktis Oncology, Inc.

        Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.

        CEO
        Matthew Roden
        Employees
        79
        Beta
        0.45

        Explore

        Frequently asked questions

        What is the intrinsic value of Aktis Oncology, Inc. (AKTS)?

        InvestorsCraft does not currently publish an intrinsic value for AKTS. How the IC value is calculated.

        Is AKTS undervalued?

        InvestorsCraft does not publish an undervaluation signal for AKTS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.